K. pneumoniae is frequently the source of hospital-acquired infections and, due to the widespread use of antibiotics in these settings, has also acquired numerous resistance genes. In fact, over ...

Commit Biologics (“Commit”), a biotechnology company pioneering complement system activation and backed by €21.5 million in ...

The story of Q32 Bio, a company that develops therapeutics for inflammatory and autoimmune diseases, started two decades ago. That's when V. Michael Holers, MD, a University of Colorado School of ...

Newco Commit Biologics ApS has arrived on the scene after raising €16 million (US$17.2 million) in a seed round to advance bispecific antibodies that are designed to activate the complement system and ...

Long Covid patients suffer from chronic symptoms such as fatigue or shortness of breath. As researchers have discovered, this is to some extent due to a part of our immune system called the complement ...